# Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/ovarian-cancer-fallopian-tube-cancer-primary-peritoneal-cancer

> 4 upcoming FDA catalysts in ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer: REGN10597 (REGN) on Jun to Sep 2028 (topline data readout); REGN10597 (REGN) on June 2028 (primary completion); sacituzumab tirumotecan (MRK) on Apr to Jul 2029 (topline data readout); sacituzumab tirumotecan (MRK) on April 2029 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun to Sep 2028 | [REGN10597 topline data readout](https://sec-api.dev/pdufa/regn10597) | REGN | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | scheduled | "NCT06787612 (Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06787612)) |
| June 2028 | [REGN10597 primary completion](https://sec-api.dev/pdufa/regn10597) | REGN | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | scheduled | "NCT06787612 (Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06787612)) |
| Apr to Jul 2029 | [Sacituzumab tirumotecan topline data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | scheduled | "NCT06824467 (A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824467)) |
| April 2029 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | scheduled | "NCT06824467 (A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824467)) |

## Drugs

- [REGN10597](https://sec-api.dev/pdufa/regn10597) (REGN)
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/ovarian-cancer-fallopian-tube-cancer-primary-peritoneal-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/ovarian-cancer-fallopian-tube-cancer-primary-peritoneal-cancer

```bibtex
@misc{secapidev_indications_ovarian_cancer_fallopian_tube_cancer_primary_peritoneal_cancer_20261116,
  title        = {Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/ovarian-cancer-fallopian-tube-cancer-primary-peritoneal-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_ovarian_cancer_fallopian_tube_cancer_primary_peritoneal_cancer_20261116","title":"Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/ovarian-cancer-fallopian-tube-cancer-primary-peritoneal-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
